The European Medicines Agency approved rilpivirine and cabotegravir sold as Rekambys and Vocabria, respectively, and together as Cabenuva, for treating patients with HIV-1. The US FDA also approved cabotegravir as a prophylactic for HIV prevention. The World Health Organization supported the use of long-acting injectable cabotegravir as a prophylactic in July 2022.
PrEP is recommended for at-risk individuals, PEP is for those who had contact with HIV, and ART aids individuals in lowering viral load and supporting their immune response. Injectable options provide alternatives to daily pill regimens, enhancing compliance and convenience in HIV prevention and treatment.
[
Collection
]
[
|
...
]